Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Lung Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 Am J Respir Crit Care Med
2 Ann Surg Oncol
1 Anticancer Res
4 BMC Cancer
1 Br J Cancer
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Sci
5 Clin Exp Metastasis
1 Clin Lung Cancer
1 Clin Nucl Med
2 Int J Oncol
1 J Cancer Res Clin Oncol
1 J Immunol
1 J Thorac Cardiovasc Surg
1 J Thorac Oncol
1 JAMA Oncol
1 Lancet Oncol
9 Lung Cancer
1 N Engl J Med
5 Oncol Rep
2 Oncologist
4 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. OHNO Y, Takeshi Y, Takenaka D, Koyama H, et al
    Comparison of Diagnostic Accuracy for TNM Stage Among Whole-Body MRI and Coregistered PET/MRI Using 1.5-T and 3-T MRI Systems and Integrated PET/CT for Non-Small Cell Lung Cancer.
    AJR Am J Roentgenol. 2020 Sep 22:1-8. doi: 10.2214/AJR.19.22565.
    PubMed         Abstract available

    Am J Respir Crit Care Med

  2. SMITH JA, Harle A, Dockry R, Holt K, et al
    Aprepitant For Cough in Lung Cancer: A Randomised Placebo-Controlled Trial and Mechanistic Insights.
    Am J Respir Crit Care Med. 2020 Sep 23. doi: 10.1164/rccm.202006-2359.
    PubMed         Abstract available

    Ann Surg Oncol

  3. CHEN D, Ding Q, Wang W, Chen C, et al
    ASO Author Reflections: Old Song, New Sung-Extracapsular Extension in Lung Cancer in the Era of Eighth-Edition N Classification.
    Ann Surg Oncol. 2020 Sep 22. pii: 10.1245/s10434-020-09173.

    Evaluation of Eighth AJCC TNM Sage for Lung Cancer NSCLC: A Meta-analysis.
    Ann Surg Oncol. 2020 Sep 20. pii: 10.1245/s10434-020-09151.
    PubMed         Abstract available

    Anticancer Res

  5. SUGISAWA N, Hamada K, Han Q, Yamamoto J, et al
    Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Anticancer Res. 2020;40:4869-4874.
    PubMed         Abstract available

    BMC Cancer

  6. GAO W, Liang J, Ye Y, Lu J, et al
    FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis.
    BMC Cancer. 2020;20:895.
    PubMed         Abstract available

  7. LI L, Yue HC, Han YW, Liu W, et al
    Relationship between the invasion of lymphocytes and cytokines in the tumor microenvironment and the interval after single brachytherapy hypofractionated radiotherapy and conventional fractionation radiotherapy in non-small cell lung Cancer.
    BMC Cancer. 2020;20:893.
    PubMed         Abstract available

  8. GRIESHOBER L, Graw S, Barnett MJ, Thornquist MD, et al
    AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality.
    BMC Cancer. 2020;20:905.
    PubMed         Abstract available

  9. XU X, Liu Z, Xiong W, Qiu M, et al
    Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China.
    BMC Cancer. 2020;20:903.
    PubMed         Abstract available


  10. ZHANG Y, Birmann BM, Han J, Giovannucci EL, et al
    Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study.
    BMJ. 2020;370:m2942.
    PubMed         Abstract available

    Br J Cancer

  11. KIM TW, Hong DW, Park JW, Hong SH, et al
    CB11, a novel purine-based PPAR ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells.
    Br J Cancer. 2020 Sep 22. pii: 10.1038/s41416-020-01088.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  12. WAH W, Stirling RG, Ahern S, Earnest A, et al
    Cancer Epidemiol Biomarkers Prev. 2020 Sep 18. pii: 1055-9965.EPI-20-0709.
    PubMed         Abstract available

    Cancer Sci

  13. NISHIO M, Seto T, Reck M, Garon EB, et al
    Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
    Cancer Sci. 2020 Sep 20. doi: 10.1111/cas.14655.
    PubMed         Abstract available

    Clin Exp Metastasis

  14. YANG H, He D, Wang F, Deng Q, et al
    A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
    Clin Exp Metastasis. 2020;37:391-399.
    PubMed         Abstract available

  15. GARDNER AB, Charo LM, Mann AK, Kapp DS, et al
    Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes.
    Clin Exp Metastasis. 2019 Nov 22. pii: 10.1007/s10585-019-10007.
    PubMed         Abstract available

  16. RAZMARA AM, Sollier E, Kisirkoi GN, Baker SW, et al
    Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Clin Exp Metastasis. 2020 Apr 25. pii: 10.1007/s10585-020-10033.
    PubMed         Abstract available

  17. XI Y, Qi Z, Ma J, Chen Y, et al
    PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.
    Clin Exp Metastasis. 2020;37:173-185.
    PubMed         Abstract available

  18. METCALF S, Dougherty S, Kruer T, Hasan N, et al
    Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer.
    Clin Exp Metastasis. 2019 Oct 19. pii: 10.1007/s10585-019-10000.
    PubMed         Abstract available

    Clin Lung Cancer

  19. BONOMI M, Maltese M, Brighenti M, Muri M, et al
    Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy.
    Clin Lung Cancer. 2020 Aug 26. pii: S1525-7304(20)30254.

    Clin Nucl Med

  20. SHARMA P
    68Ga-PSMA-Avid Small Cell Lung Cancer on PET/CT: Incidental Second Malignancy in Treated Prostate Cancer.
    Clin Nucl Med. 2020 Sep 15. doi: 10.1097/RLU.0000000000003270.
    PubMed         Abstract available

    Int J Oncol

  21. SHEN Q, Xu Z, Xu S
    Long noncoding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR514a3p/ULK1 axis in human nonsmall cell lung cancer.
    Int J Oncol. 2020 Aug 7. doi: 10.3892/ijo.2020.5106.
    PubMed         Abstract available

  22. SHEN M, Chen Y, Xu L, Zhu R, et al
    [Corrigendum] Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells.
    Int J Oncol. 2020 Aug 19. doi: 10.3892/ijo.2020.5113.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  23. JIANG Y, Su Z, Li C, Wang R, et al
    Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.
    J Cancer Res Clin Oncol. 2020 Sep 23. pii: 10.1007/s00432-020-03394.
    PubMed         Abstract available

    J Immunol

  24. GHOUSE SM, Vadrevu SK, Manne S, Reese B, et al
    Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis.
    J Immunol. 2020;204:990-1000.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  25. BRUNELLI A, Chaudhuri N, Kefaloyannis M, Milton R, et al
    Eurolung risk score is associated with long-term survival after curative resection for lung cancer.
    J Thorac Cardiovasc Surg. 2020 Aug 24. pii: S0022-5223(20)32431.
    PubMed         Abstract available

    J Thorac Oncol

  26. KANG J, Jeong SM, Shin DW, Cho M, et al
    Associations of aspirin, statins, and metformin with lung cancer risk and related mortality: time-dependent analysis of population-based nationally representative data.
    J Thorac Oncol. 2020 Sep 12. pii: S1556-0864(20)30712.
    PubMed         Abstract available

    JAMA Oncol

  27. BLAYNEY DW, Zhang Q, Feng J, Zhao Y, et al
    Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2020 Sep 24. pii: 2770700. doi: 10.1001/jamaoncol.2020.4429.
    PubMed         Abstract available

    Lancet Oncol

  28. NOWAK AK, Lesterhuis WJ, Kok PS, Brown C, et al
    Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Lancet Oncol. 2020;21:1213-1223.
    PubMed         Abstract available

    Lung Cancer

  29. CHEN H, Louie AV
    High risk, same reward?
    Lung Cancer. 2020;145:221.

  30. BALDINI E, Tibaldi C
    A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."
    Lung Cancer. 2020;145:226.

  31. CHEN D, Chen C, Chen Y
    Letter to the editor concerning 'Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer'.
    Lung Cancer. 2020;144:92.

  32. INDINI A, Rijavec E, Grossi F
    Immune related adverse events and response to immunotherapy: Focus on corticosteroids.
    Lung Cancer. 2020;145:225.

  33. LIU X, Hong L, Nilsson M, Hubert SM, et al
    Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2020;149:33-40.
    PubMed         Abstract available

  34. VOONG KR, Naidoo J
    Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer.
    Lung Cancer. 2020 Sep 5. pii: S0169-5002(20)30596.

  35. GOLDMAN JW, Garassino MC, Chen Y, Ozguroglu M, et al
    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Lung Cancer. 2020;149:46-52.
    PubMed         Abstract available

  36. LI J, Wang Y, Zhang B, Xu J, et al
    Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
    Lung Cancer. 2020;149:17-22.
    PubMed         Abstract available

  37. REISSIG TM, Sara L, Ting S, Reis H, et al
    ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
    Lung Cancer. 2020;149:10-16.
    PubMed         Abstract available

    N Engl J Med

  38. WU YL, Tsuboi M, He J, John T, et al
    Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
    N Engl J Med. 2020 Sep 19. doi: 10.1056/NEJMoa2027071.
    PubMed         Abstract available

    Oncol Rep

  39. LI D, Wang L, Feng J, Shen YW, et al
    RP11284F21.9 promotes lung carcinoma proliferation and invasion via the regulation of miR6273p/CCAR1.
    Oncol Rep. 2020 Aug 12. doi: 10.3892/or.2020.7732.
    PubMed         Abstract available

  40. CHEN L, Ren P, Zhang Y, Gong B, et al
    Long noncoding RNA GAS5 increases the radiosensitivity of A549 cells through interaction with the miR21/PTEN/Akt axis.
    Oncol Rep. 2020;43:897-907.
    PubMed         Abstract available

  41. GUAN Y, Yang J, Liu X, Chu L, et al
    Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of nonsmallcell lung cancer by sponging microRNA5093p and competitively upregulating HDAC9 expression.
    Oncol Rep. 2020 Aug 7. doi: 10.3892/or.2020.7719.
    PubMed         Abstract available

  42. GAO F, Li M, Zhou L, Liu W, et al
    Xanthohumol targets the ERK1/2Fra1 signaling axis to reduce cyclin D1 expression and inhibit nonsmall cell lung cancer.
    Oncol Rep. 2020 Jul 20. doi: 10.3892/or.2020.7697.
    PubMed         Abstract available

  43. WANG L, Wu L, Pang J
    Long noncoding RNA PSMA3AS1 functions as a microRNA4093p sponge to promote the progression of nonsmall cell lung carcinoma by targeting spindlin 1.
    Oncol Rep. 2020 Jul 15. doi: 10.3892/or.2020.7693.
    PubMed         Abstract available


  44. WONG ML, Gao J, Thanarajasingam G, Sloan JA, et al
    Expanding beyond maximum grade: Chemotherapy toxicity over time by age and performance status in advanced non-small cell lung cancer in CALGB 9730 (Alliance A151729).
    Oncologist. 2020 Sep 20. doi: 10.1002/onco.13527.
    PubMed         Abstract available

  45. SEHGAL K, Rangachari D, VanderLaan PA, Kobayashi SS, et al
    Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Oncologist. 2020 Sep 24. doi: 10.1002/onco.13537.
    PubMed         Abstract available

    PLoS One

  46. SCHUZ J, Bukhtiyarov I, Olsson A, Moissonnier M, et al
    Occupational cohort study of current and former workers exposed to chrysotile in mine and processing facilities in Asbest, the Russian Federation: Cohort profile of the Asbest Chrysotile Cohort study.
    PLoS One. 2020;15:e0236475.
    PubMed         Abstract available

  47. THRONICKE A, Reinhold T, von Trott P, Grah C, et al
    Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.
    PLoS One. 2020;15:e0236426.
    PubMed         Abstract available

  48. HONG S, Youk T, Lee SJ, Kim KM, et al
    Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
    PLoS One. 2020;15:e0234927.
    PubMed         Abstract available

  49. LEE JY, Fan CC, Chou NL, Lin HW, et al
    PHRF1 promotes migration and invasion by modulating ZEB1 expression.
    PLoS One. 2020;15:e0236876.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  50. YING L, Du L, Zou R, Shi L, et al
    Development of a serum miRNA panel for detection of early stage non-small cell lung cancer.
    Proc Natl Acad Sci U S A. 2020 Sep 17. pii: 2006212117.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.